Nature Communications (Mar 2023)
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
- Victor Moreno,
- Maria Vieito,
- Juan Manuel Sepulveda,
- Vladimir Galvao,
- Tatiana Hernández-Guerrero,
- Bernard Doger,
- Omar Saavedra,
- Carmelo Carlo-Stella,
- Jean-Marie Michot,
- Antoine Italiano,
- Massimo Magagnoli,
- Cecilia Carpio,
- Antonio Pinto,
- Rafael Sarmiento,
- Barbara Amoroso,
- Ida Aronchik,
- Ellen Filvaroff,
- Bishoy Hanna,
- Xin Wei,
- Zariana Nikolova,
- Irene Braña
Affiliations
- Victor Moreno
- START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz
- Maria Vieito
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- Juan Manuel Sepulveda
- Hospital Universitario 12 de Octubre
- Vladimir Galvao
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- Tatiana Hernández-Guerrero
- START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz
- Bernard Doger
- START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz
- Omar Saavedra
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- Carmelo Carlo-Stella
- Department of Biological Sciences, Humanitas University, Rozzano
- Jean-Marie Michot
- Institut Gustave Roussy
- Antoine Italiano
- Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
- Massimo Magagnoli
- Department of Oncology and Hematology, Humanitas Research Hospital – IRCCS, Rozzano
- Cecilia Carpio
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- Antonio Pinto
- Hematology-Oncology & Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS
- Rafael Sarmiento
- Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company
- Barbara Amoroso
- Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company
- Ida Aronchik
- Bristol Myers Squibb
- Ellen Filvaroff
- Bristol Myers Squibb
- Bishoy Hanna
- Bristol Myers Squibb
- Xin Wei
- Bristol Myers Squibb
- Zariana Nikolova
- Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company
- Irene Braña
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- DOI
- https://doi.org/10.1038/s41467-023-36976-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
Bromodomain and extraterminal proteins (BET) are reported as targets for anticancer therapy. Here, the authors report the final results of a phase I clinical trial of the BET inhibitor trotabresib in patients with solid tumours and diffuse large B-cell lymphoma.
